Background-The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data have been published. We sought to investigate detailed pathological responses to the Absorb versus XIENCE V (XV) in a porcine coronary model with duration of implant extending from 1 to 42 months. Methods and Results-A total of 335 devices (263 Absorb and 72 XV) were implanted in 2 or 3 main coronary arteries of 136 nonatherosclerotic swine and examined by light microscopy, scanning electron microscopy, pharmacokinetics, and gel permeation chromatography analyses at various time points. Vascular responses to Absorb and XV were largely comparable at all time points, with struts being sequestered within the neointima. Inflammation was mild to moderate (with absence of inflammation at 1 month) for both devices, although the scores were greater in Absorb at 6 to 36 months. Percent area stenosis was significantly greater in Absorb than XV at all time points except at 3 months. The extent of fibrin deposition was similar between Absorb and XV, which peaked at 1 month and decreased rapidly thereafter. Histomorphometry showed expansile remodeling of Absorb-implanted arteries starting after 12 months, and lumen area was significantly greater in Absorb than XV at 36 and 42 months. These changes correlated with dismantling of Absorb seen after 12 months. Gel permeation chromatography analysis confirmed that degradation of Absorb was complete by 36 months. Conclusions-Absorb demonstrates comparable long-term safety to XV in porcine coronary arteries with mild to moderate inflammation. Although Absorb was associated with greater percent stenosis relative to XV, expansile remodeling was observed after 12 months in Absorb with significantly greater lumen area at ≥36 months. Resorption is considered complete at 36 months. (Circ Cardiovasc Interv. 2014;7:330-342.)
T he current metallic drug-eluting stents (DESs) have been shown to exhibit several limitations including a risk for hypersensitivity reaction, late stent thrombosis, and the development of neoatherosclerosis as well as an impaired vasomotion and inability to assess lumen dimensions by noninvasive imaging. [1] [2] [3] The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb; Abbott Vascular, Santa Clara, CA) is designed to provide transient arterial support while eluting an antiproliferative drug. The first-in-man ABSORB Cohort A trial demonstrated a low rate of major adverse cardiac events (3.3%) at 1 year with restored vasomotion and late lumen enlargement at 2 years in patients with a single de novo native coronary artery lesion, 4, 5 although the potential benefit of these outcomes over metallic DESs needs to be proven in randomized clinical trials. The ABSORB Cohort B trial also showed safety and efficacy with major adverse cardiac event rate of 9.0% at 2 years. 6 Although these clinical studies on Absorb have been conducted in a relatively small number of patients with simple coronary lesions, large-scale randomized clinical trials on the second-generation everolimus-eluting cobaltchromium XIENCE V (XV) stents (Abbott Vascular) in more complex lesions have shown clinical safety with similar but lower major adverse cardiac event rates: 7.1% at 2 years in the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. 7 Safety of XV is further supported by human autopsy results, with a low rate of stent thrombosis (4%) at late and very late time points. 8 The current preclinical study sought to investigate detailed pathological changes after the implant of Absorb as compared with XV in a porcine coronary model extending from 1 to 42 months (total devices evaluated: 261 Absorb). Quantitative coronary angiography assessment was performed along with pharmacokinetics and gel permeation chromatography (GPC) analyses at various time points to correlate the histological observations with the scaffold's performance in a preclinical model.
Methods

Study Devices
The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) is the same construct used in Cohort B of the ABSORB clinical trial. Absorb is a balloon-expandable, bioresorbable scaffold that consists of a poly(l-lactide) backbone coated with a poly(d, l-lactide) coating in a 1:1 ratio with everolimus. XV is a balloon-expandable cobalt-chromium stent that served as the metallic DES control for this study. Absorb and XV both have the same everolimus dose density (100 μg/cm 2 ). 9 Notably, postimplantation structural components of Absorb are referred to as struts from time of implantation to 30 months, whereas the term resorption site is applied to denote the location of pre-existing structural components of Absorb at ≥36 months. Resorption site is defined as hydration and replacement of the scaffold strut by infiltrating proteinaceous material and connective tissue.
Experimental Model
The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee, and the study was conducted in compliance with the Food and Drug Administration Good Laboratory Practice regulations. Fifty nonatherosclerotic healthy Yorkshire crossbred farm swine (≤3 months) and 86 Yucatan mini swine (6-42 months) underwent device implantation with a targeted balloon-to-artery ratio of 1.0 to 1.1 (for details, see Methods in the Data Supplement). Each animal received a single Absorb or XV implant (3.0×18 mm for 1, 3, and 6 months and 3.0×12 mm for 12 to 42 months) in 2 or 3 main coronary arteries. Absorb and XV were implanted according to a predetermined stratified matrix, and animals were randomly assigned to the matrix. Consequently, a total of 335 devices (263 Absorb and 72 XV) were implanted in 136 animals. One Yorkshire crossbred farm swine with 2 Absorb and 1 XV died 1 hour postimplantation from unknown cause and was excluded from the analysis; however, the implants were intact without defect or thrombus. Seventy-one animals were euthanized and examined at 1 (n=19 devices), 3 (n=21), 6 (n=21), 12 (n=21), 18 (n=19), 24 (n=19), 30 (n=20), 36 (n=20), and 42 months (n=21) by light microscopy or scanning electron microscopy (SEM; 110 Absorb and 71 XV; Table 1 ). In addition to light microscopy and SEM analysis, pharmacokinetic studies were performed in 24 animals (53 Absorb) and GPC analysis in 40 animals (98 Absorb) at various time points (Tables 1 and 2 ). Quantitative coronary angiography assessment was also performed on all animals designated for light microscopy and SEM. The details of the methods for quantitative coronary angiography, SEM, pharmacokinetics, and GPC analyses are described in Methods in the Data Supplement.
Histological Preparation
Hearts were excised and perfusion fixed with 10% neutral buffered formalin at 80 to 100 mm Hg. The implanted coronary arteries were dissected from the heart, radiographed, dehydrated in graded series of ethanol solutions, and embedded in methyl methacrylate plastic. After polymerization, 2-to 3-mm sections were sawed, and 3 segments from the proximal, mid, and distal portions of each device were sectioned. Histological sections were cut at 6 μm and stained with hematoxylin and eosin and Movat pentachrome for light microscopic assessment.
Histological Analysis
Histological sections were measured with computer assist software (IPLab, Scanalytics, Rockville, MD) as previously described. 10 Measurements included the cross-sectional areas for external elastic lamina, internal elastic lamina (IEL), and lumen. The percent stenosis was calculated using the following formula: (1−[lumen area/IEL area])×100. The results of external elastic lamina, IEL, and lumen area measurements are also being reported in a separate manuscript.
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Neointimal thickness was measured and defined as the distance from the inner surface of each strut/resorption site to the luminal border. Because Absorb resorption sites become difficult to identify over time, estimates of neointimal thickness were used at later time points (30-42 months). Giant cell reaction was expressed as a percentage of the total number of struts/resorption sites in each section. Vessel injury score was scored according to the method by Schwartz et al. 12 Neointimal inflammation (0-4) and fibrin deposition (0-3) were semiquantitatively scored for each section as previously described.
8,13
Statistical Analysis
Results for continuous variables with normal distribution were expressed as mean±SD. Normality of distribution was tested by the Shapiro-Wilk test. Variables with non-normal distribution were expressed as median and 25th to 75th percentiles. Integrated linear generalized estimating equation modeling with an assumed Gaussian distribution, an identity link function, and a compound symmetry structure for working correlation matrix was used for the comparisons of continuous variables between Absorb and XV to account for the longitudinal structure of device usage within the same animals. Dependent variables with non-normal distribution were logarithmically transformed before the analyses. All analyses were performed with JMP 5 (SAS Institute Inc, Cary, NC) and SAS version 9.2 (SAS Institute Inc). The statistical tests were 2 tailed, and a value of P<0.05 was considered to be of statistical interest.
WHAT IS KNOWN
• Clinical studies have demonstrated the safety and efficacy of the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) in a relatively small number of patients with simple coronary lesions; however, only limited preclinical data have been reported.
• Large-scale randomized clinical trials involving more complex coronary lesions, along with human pathological studies, have shown the safety of the second-generation everolimus-eluting cobalt-chromium XIENCE V (XV) stents with a low rate of late and very late stent thrombosis.
WHAT THE STUDY ADDS
• Absorb demonstrated comparable safety to XV in a normal porcine coronary artery model ≤42 months after implantation with low-grade inflammation and fibrin deposition. Inflammation scores were greater in Absorb compared with XV at 6 to 36 months; however, inflammation scores for Absorb decreased with time.
• Histomorphometric analyses showed late lumen and vessel enlargement in Absorb-implanted arteries starting after 12 months.
• Histomorphologic changes of Absorb dismantling were observed after 12 months, and resorption sites of Absorb were poorly discernible to essentially absent at 42 months.
• Gel permeation chromatography analysis confirmed that degradation of Absorb was complete by 36 months.
Results
Angiographic Analysis
Coronary angiography demonstrated mild luminal narrowing at 1 month and moderate luminal narrowing at 3 months for both Absorb and XV; however, the degree of luminal narrowing became much less thereafter, and at 42 months, smooth lumen contours were observed in both devices. Balloonto-artery ratio in each group remained similar for all time points, although XV showed greater balloon-to-artery ratio as compared with Absorb at each time point (Table 3) . Both Absorb and XV tended to show larger follow-up mean luminal diameter at later time points as compared with earlier time points with the exception of 36 months at which time both Absorb and XV were of similar size to <18 months. Late lumen loss and percent diameter stenosis were greater for Absorb as compared with XV at 1 to 6 months, followed by comparable late loss and percent diameter stenosis between the groups at 12 to 24 months. Absorb exhibited lower late loss and smaller percent diameter stenosis as compared with XV from 30 to 42 months, where the difference was statistically significant at 36 months. Late loss and percent diameter stenosis were maximal at 3 months for both Absorb and XV but decreased thereafter for both implants ≤12 months, and the decrease was more remarkable for Absorb than XV after 12 months (Table 3) .
Histological Analysis
Light microscopic assessment revealed that vascular responses to Absorb were largely comparable with those to XV at all time points (Figures 1 and 2 ) with patent stents/scaffold and near (1 month) to complete (>1 month) sequestration of struts within the neointima. Neither Absorb nor XV showed evidence of luminal thrombosis of either the main or the side branch of coronary arteries.
Morphometric analysis showed expansile vessel remodeling in Absorb-implanted arteries starting at 12 months, whereas XV showed no changes in external elastic lamina or IEL areas ( Figure 3 , Table 4 ). Increased vessel area in Absorb was observed after 12 months, was most dramatic at 18 months, and followed at a slower rate of enlargement after 18 months. In contrast, XV showed minimal change in vessel size throughout the period of observation. The lumen area paralleled the changes observed in IEL. The percent area stenosis was significantly greater in Absorb at all time points except at 3 months as compared with XV and peaked at 3 to 6 months for both Absorb and XV. Neointimal thickness was also significantly greater in Absorb than XV at all time points except at 3 months. However, the lumen area enlarged after 12 months, which was only seen in Absorb, and the difference in lumen area between the devices reached statistical significance at 36 and 42 months. At 36 and 42 months, Absorb showed greater percent area stenosis (26.4±6.1% and 24.5±4.9%, respectively) as compared with XV (19.4±8.8% and 16.0±1.6%, respectively); however, the effective lumen was larger in Absorb as compared with XV. Quantitative coronary angiography assessment was performed on all animals for light microscopy and SEM. Absorb indicates Absorb bioresorbable vascular scaffold; GPC, gel permeation chromatography; and SEM, scanning electron microscopy.
*Twelve Absorb and 7 XIENCE V were implanted in 7 pigs for light microscopic assessment at 1 month; however, 1 animal with 2 Absorb and 1 XIENCE V died 1 hour postimplantation from unknown cause and was excluded from the analysis.
†One animal with 1 Absorb and 1 XIENCE V for light microscopic assessment at 42 months was euthanized at 40 months because of health issues; however, the vascular responses observed in this animal was comparable with that observed in other animals examined at 42 months and therefore the animal was included into the 42 months group. Injury scores were generally low and comparable within the groups ≤30 months, although the score was greater for Absorb as compared with XV despite lower balloon-to-artery ratio in the former, and the difference was statistically significant at 12 months ( Figure 3 , Table 4 ). Inflammation was overall mild to moderate for both devices, with absence of inflammation at 1 month in Absorb and XV. However, granulomas were observed in 3 of 102 in Absorb (1 at 3 months and 2 at 12 months) and in 4 of 67 XV (3 at 3 months and 1 at 12 months). Although inflammation scores were significantly greater for Absorb than XV from 6 to 36 months except for 24 months, the scores progressively declined after 18 months in Absorb (P<0.001) for the comparison across time (18-42 months). Both devices exhibited absent or minimal inflammation at 42 months. After exclusion of the stents/scaffold with granulomas, the inflammatory infiltrate was minimal to mild and consisted mostly of macrophages and a few lymphocytes (Figures 2 and 3 ). Giant cells were the most frequently observed at 1 month in both devices; however, they were uncommon after 3 months, and there was no significant difference between the devices (Figures 2 and 3 ). The extent of fibrin deposition was similar in both groups; peak fibrin deposition was seen at 1 month with rapid decrease at 3 months and becoming absent or minimal at ≥6 months (Figures 2 and 3 ). Minor areas of calcification were identified around struts/resorption sites of Absorb at all time points (Figure 2 ), although these are interpreted to relate to preexisting poly(d, l-lactide) coating and are likely an inconsequential feature.
There were 2 time-dependent aspects appreciated with struts/resorption sites of Absorb, both of which are a reflection of the scaffold's transience: increasing observation of discontinuities and eosinophilic staining of the resorption sites by hematoxylin and eosin and blue staining by Movat stain. Discontinuities, defined as sites in which struts/resorption sites deviated from the conventional box shape with integration of arterial derived tissue, were increasingly observed with time, especially at time points after 12 months. In addition, beginning at 18 months, resorption sites underwent color changes that included alcian blue positive staining at 18 and 24 months with Movat pentachrome and increasing eosinophilia with hematoxylin and eosin thereafter (Figures 1 and  2 , respectively). In concert with both of these chronological changes, there was increasing integration of arterial tissue into resorption sites such that by 42 months sites were often completely replaced by collagen and proteoglycans with sparse Although all arteries implanted with Absorb and XV were patent without evidence of thrombus formation, there were 2 arteries (1 each at 1 and 3 months) implanted with Absorb in which overlaid struts, struts incompletely apposed to the IEL, and strut discontinuities were observed (Figure 4 ). In the artery evaluated at 1 month, these observations were present in the mid to distal sections of the artery, whereas similar observations were located proximally in the artery evaluated at 3 months. Both Absorbs had been implanted in the left anterior descending artery and had received a second inflation proximally to ensure apposition. Both arteries had near (1 month) to complete (3 months) neointimal coverage of all struts, including those struts that deviated from their expected location. The maximum percent stenosis as assessed histologically in these arteries at 1 and 3 months were 39% (distal) and 65% (proximal), respectively, which related to the increased neointimal proliferation that occurred in relation to the overlaid struts. In neither artery was excess neointimal or adventitial inflammation nor injury to the artery wall observed; however, fibrin was observed at these sites. Additional evaluation of the myocardium of these animals showed no evidence of thromboembolization in relation to the site of implant.
Scanning Electron Microscopy
At 1 month, both Absorb and XV showed complete strut coverage with mild neointimal growth such that the underlying outline of the struts could be clearly identified. The luminal surface appeared 100% endothelialized with cells arranged in cobblestone morphology and showing generally tight and well-formed cell-to-cell contacts ( Figure 5 ). Rapid endothelial coverage observed at 1 month was maintained to the final SEM follow-up at 12 months for both Absorb and XV (Figure 5) ; however, only 2 devices for Absorb and 1 for XV were evaluated at each time point.
Pharmacokinetics
The mean cumulative percentage of everolimus released during the first 28 days was 79%, with 35% being released during the first 24 hours. Everolimus release peaked at 90 days (96%) after implantation of Absorb ( Figure 6A ). The maximum everolimus concentration in scaffolded arterial segments occurred at 3 hours after implantation with a mean of 16.2 ng/mg ( Figure 6B ). For the effectiveness of inhibition of human SMC proliferation, everolimus concentrations in the target vessels for the first 28 days postimplant should be maintained at levels minimally greater than the IC 50 of SMC. 14 The results showed that everolimus arterial concentrations ranged from 2.3 to 4.6 ng/mg from 1 to 28 days, which were greater than the IC 50 of SMC. The levels decreased to 0.6 ng/mg by 90 days postimplantation. Peak levels of everolimus in the adjoining nonscaffolded segments were 0.7% of that in scaffolded segments in the proximal region and 1.7% in the distal region. The peak concentration (C max ) of everolimus in blood was 3.75±0.96 ng/mL at 15 minutes after deployment of three 3.0×18 mm Absorbs in 1 animal. For systemic safety, it is desirable that the drug concentrations in blood are at levels <3 ng/mL which is the minimally effective concentration for immunosuppression in organ transplant patients. 15 The blood levels of everolimus quickly declined to below the limit of quantification (<0.1 ng/mL) after 168 hours (7 days) ( Figure 6C ). Everolimus in the myocardium subjacent to scaffold implanted arteries was 0.71 ng/mg and was measured at 3 hours postimplantation. It quickly decreased to minimally quantifiable levels (0.01 ng/mg) by 7 to 14 days. In the lungs, kidneys, spleen, and liver, the drug was only measurable (0.01-0.02 ng/mg) at 3 hours.
Gel Permeation Chromatography
The GPC results indicated that the weight-average molecular weight, number-average molecular weight, and polydispersity index of polymer decreased over time. number-average molecular weight decreased slowly by ≈18% during the first 6 months of scaffold implantation followed by a more rapid decline thereafter (by 49%, 72%, and 93% at 12, 18, and 24 months, respectively; Figure 7A ). The polymer number-average molecular weight dropped to below the measurement limit (4.7 kDa) at 30 months after implantation. The percent mass loss of polymer increased slowly by ≈10% during the first 18 months, followed by a rapid increase thereafter (by 31%, 74%, and 97% at 24, 30, and 36 months, respectively), becoming undetectable at 42 months (limit of detection, 0.1 mg/mL of polymer, ie, 1.9% of the gravimetric weight of the stent at T0 [5.3 mg]; Figure 7B ). In the 36-month chromatograms, only a small peak below the limit of quantification of polymer (0.3 mg/mL) was observed ( Figure 7C ), indicating the polymer is fully resorbed at 36 months after implantation.
Discussion
The principal findings in the current preclinical study are as follows: (1) Absorb shows comparable safety to XV in porcine coronary arteries at all time points with patent stents/scaffold and near (1 month) to complete (>1 month) sequestration of struts within the neointima; (2) mild to moderate inflammation was observed in Absorb which was greater as compared with XV at 6 to 36 months, although inflammation decreased with time; (3) percent area stenosis was greater in Absorb than in XV at all time points except at 3 months, whereas late vessel and lumen enlargement was observed for Absorbimplanted arteries after 12 months; (4) histological changes of Absorb dismantling were observed after 12 months, and resorption sites of Absorb were poorly discernible to essentially absent at 42 months; (5) GPC analysis confirmed that degradation of Absorb was complete by 36 months; and (6) pharmacokinetic studies of everolimus release in Absorb was similar to previously published XV data. These findings not only support the long-term safety of Absorb, but also show lumen enlargement overtime with mild to moderate inflammation. The current preclinical study of Absorb demonstrates the unique characteristics of the scaffold with its ability to allow for lumen enlargement, thus distinguishing it from metallic stents. Delayed arterial healing with poor strut coverage has been shown to be the primary substrate responsible for late and very late stent thrombosis after the first-generation sirolimus-and paclitaxel-eluting stent placement. 16 Autopsy studies have demonstrated divergent mechanisms of late and very late stent thrombosis between sirolimus-and paclitaxel-eluting stents, that is, hypersensitivity reaction to the permanent polymer with extensive inflammation consisting of eosinophils and The analyses include devices with granulomas which were observed in 3 of 102 Absorb (2.9%; 1 at 3 months and 2 at 12 months) and 4 of 67 XIENCE V (6.0%; 3 at 3 months and 1 at 12 months). Eosinophil infiltration was absent in both devices except in stents/scaffolds that have a granulomatous reaction, and in these, the number of eosinophils per high-power field varied from 2 to 50 cells which were observed along with lymphocytes and macrophages.
Values are expressed as mean±SD or median (25th-75th percentile). Absorb indicates Absorb everolimus-eluting bioresorbable vascular scaffold; EEL, external elastic lamina; and IEL, internal elastic lamina. *P value for the comparison across all time points. †P value for interaction with time and device. ‡P value for Absorb vs XIENCE V at each time point.
lymphocytes in the former and malapposition with excessive fibrin deposition in the latter. 1 However, the second-generation XV stents are safer as compared with the first-generation DESs in both clinical and pathological studies, where XV exhibit lower frequency of late and very late stent thrombosis with a strikingly lower prevalence of uncovered struts, less inflammation, and less fibrin deposition versus sirolimus-and paclitaxel-eluting stents. 8, 17, 18 The current preclinical study showed that Absorb exhibited comparable safety to XV, with near (1 month) to complete (>1 month) sequestration of struts within neointima without evidence of thrombosis.
Vascular inflammation plays a crucial role in device outcomes because it has been shown to be associated with neointimal growth and restenosis. The current study showed mild to moderate inflammation in Absorb through 42 months. However, Absorb exhibited greater inflammation scores as compared with XV from 6 to 36 months. Nevertheless, the inflammation score, although greater in Absorb, was generally <1 except at 12, 18, 30, and 36 months with 75th percentile reaching >1. Greater inflammation has been correlated with greater neointimal thickness and area stenosis in bare metal stents and DESs. 19, 20 It has been reported that the rate of degradation affects the degree of inflammatory response. 21 Thus, it may be hypothesized that inflammation associated with Absorb is related to polymer resorption. However, the observed inflammation in the LAD with Absorb at 3 months with overlaid struts (black arrowheads) and atypical strut alignment (white arrowhead). Note complete neointimal coverage of all struts in both arteries with increased neointimal growth; however, in both arteries, the lumens remained patent.
progressively decreased after 18 months, which is the same period during which the most rapid mass loss occurred. Macrophages, which feature diverse and plastic phenotypes, influence endothelial proliferation and angiogenesis together with SMC infiltration and collagen deposition, all of which are required for healing and tissue remodeling. 22 At 42 months, there was absence to minimal inflammation when the scaffold is largely resorbed and replaced by matrix consisting of collagen and proteoglycan with infrequent spindle The mean cumulative percentage of everolimus released during the first 28 days was 79% and drug release peaked at 90 days (96%). B, Everolimus concentration in scaffolded arterial segments was the greatest at 3 hours after implantation with a mean concentration being 16.2 ng/mg. Arterial everolimus concentrations ranged from 2.3 to 4.6 ng/mg in 1 to 28 days, which were greater than IC 50 of smooth muscle cell (SMC) that is required for the inhibition of human SMC proliferation. (C) The concentration of everolimus in blood peaked at 15 minutes after Absorb implantation with a mean value being 3.75 ng/mL and quickly declined to below the limit of quantification (<0.1 ng/mL) after 168 hours (7 days). cells; no inflammatory cells were observed in these regions. The absence or minimal inflammation with largely restored morphological appearance of Absorb-implanted arteries at 42 months indicates that there were no untoward effects of degradation, because the inflammatory response was controlled because of the gradual degradation of the scaffold during a 3-year period. Moreover, the restored morphological appearance of arteries along with the observed expansile remodeling suggests that the inflammation in Absorb-implanted arteries at 6 to 36 months precedes the arterial repair and remodeling. 23 Fibrin deposition is considered to be one of the biological signs of antiproliferative drug effects. The current study showed similar extent of fibrin deposition between Absorb and XV, which peaked at 1 month and rapidly decreased at 3 months followed by absent or minimal deposition at ≥6 months. Comparable healing processes with decreasing fibrin deposition in Absorb and XV are attributable to similarity in drug release kinetics between the 2 devices as shown in the current pharmacokinetics profile. It is also known that fibrin degradation products can induce SMC migration and proliferation. 24 However, because of less release of the drug after 1 month, it is likely that fibrin deposition is replaced by neointimal tissue in both Absorb and XV, which is supported by similar response cures with peak neointimal growth at 3 to 6 months with regression thereafter attributable to replacement of proteoglycans by collagen followed by cross-linking of collagen that results in a reduction in the neointimal thickness.
The neointimal thickness and percent area stenosis were almost always greater in Absorb as compared with XV, which might be at least partly attributable to thicker strut thickness in Absorb (156 μm) versus XV (97 μm). The neointimal thickness in Absorb did not decrease with time but remained similar after 12 months, whereas in XV, the neointima decreased at ≥12 months. Nevertheless, the lumen area, which is the source of oxygenation and other nutrients to the myocardial bed, was significantly greater in Absorb than XV at 36 and 42 months. The drawbacks (increased stenosis and greater neointimal thickness) of the Absorb scaffold seen at early time points were no longer pertinent at ≥36 months. These changes can be equated to those observed in nonsignificant atherosclerotic stenosis (≤40%) observed in humans that does not result in lumen compromise. 25 The current study also showed a lower balloon-to-artery ratio in Absorb as compared with XV, whereas injury score was generally greater in Absorb than XV where the difference was significant at 12 months. These results are consistent with the fact that the balloon-to-artery ratio does not always correspond to injury scores. 26 Nevertheless, it is possible that because of greater thickness and radiolucency of the scaffold strut, the balloon-to-artery ratio would be less.
There were 2 Absorbs with histological observations suggestive of premature scaffold fracture. Although not specifically known, the inflation rates used during implantation of these scaffolds may have exceeded those detailed in the instruction for use for Absorb (2 atm per 5 seconds). Although these observations impacted the degree of lumen narrowing in both arteries, the arterial lumens remained patent, and there were no adverse responses in the distal myocardial beds.
GPC analysis parallels histological observations in that minimal mass loss and change in the scaffold's histological appearance are observed through the first 12 months. Morphological changes in the scaffold resorption sites began at 18 months but were most readily appreciated at 24 months and thereafter, which corresponds to the time when numberaverage molecular weight approaches and then falls below the limit of measurement. Similarly, dissolution of resorption sites with connective tissue integration is readily appreciated at 36 and 42 months when the polymer mass is at or below the limit of quantification. The vessel morphology at 42 months of Absorb-implanted arteries showed an intact media with mild neointimal thickening. As anatomy follows function, these anatomic features suggest that Absorb is likely to return the vessel to its original physiological state and reactivity although with mild intimal thickening and medial thinning as compared with the native artery.
Study Limitations
Vascular responses to the devices in healthy swine coronary arteries are likely different from those in diseased human arteries, which may limit the ability to generalize the current findings directly to clinical outcomes in humans. Inflammatory reaction may be different because no underlying inflammation was present at the time of implantation in the porcine model. The current study used 2 different species of swine (Yorkshire for 1-3 months and Yucatan for ≥6 months) and 2 different lengths of stent/scaffold (3.0×18 mm for 1-6 months and 3.0×12 mm for ≥12 months), which may have affected the vascular response to the implants. Also, Yorkshire swine have a tendency to elicit a greater inflammatory response than do Yucatan swine; however, no adverse effects were ascertained throughout the continuum of the study. It should also be noted that angiographic assessment has limited accuracy as compared with histological analysis; the latter is more reflective of the actual morphometric changes over time. SEM assessment was performed in only limited number of devices in normal arteries. Moreover, the multiple hypotheses testing attributable to the many time points could result in false statistical significance because of chance. Nevertheless, our study shows a definite safety profile of Absorb with comparable results to XV, the latter of which has been in clinical use for >8 years.
Conclusions
The Absorb bioresorbable vascular scaffold demonstrated comparable safety to XV in the normal porcine coronary arteries ≤42 months after implantation with mild to moderate inflammation and greater neointimal thickening, along with the unique response of late lumen and vessel enlargement seen at ≥36 months. Pharmacokinetic studies of release of everolimus were similar between Absorb and XV and were associated with fibrin deposition in both at 1 month. Degradation in Absorb was completed within 36 months in GPC analysis. Nevertheless, Absorb needs to be studied in large clinical trials which are currently ongoing.
